Mutagenesis at the human tachykinin NK2 receptor to define the binding site of a novel class of antagonists

被引:16
作者
Meini, S
Bellucci, F
Catalani, C
Cucchi, P
Patacchini, R
Rotondaro, L
Altamura, M
Giuliani, S
Giolitti, A
Maggi, CA
机构
[1] Menarini Ric SpA, Dept Pharmacol, Florence, Italy
[2] Menarini Biotech, Dept Biotechnol, Rome, Italy
[3] Menarini Ric, Dept Chem, Florence, Italy
[4] Menarini Ric, Dept Drug Design, Florence, Italy
关键词
binding site; G protein-coupled receptor; molecular modelling; nonpeptide antagonists; site-directed mutagenesis;
D O I
10.1016/j.ejphar.2004.02.016
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacological profile of novel antagonists endowed with high affinity for the human tachykinin NK2 receptor is presented. MEN13918 (Ngamma{Nalpha[Nalpha(benzo[b]thiophen-2-yl)carbonyl]-1-aminocyclohexan-1-carboxy]-D-phenylalanyl}-3-cis-aminocyclohexan-1-carboxylic-acid-N-(1S,2R)-2-aminocyclohexyl)amide trifluoroacetate salt) and MEN14268 (Nalpha[Nalpha(benzo[b]thiophen-2-yl)carbonyl)-1-aminocyclopentane-1-carboxyl]-D-phenylalanine-N-[3(morpholin-4-yl)propyl]amide trifluoroacetate salt) were more potent in blocking neurokinin A (NKA, His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2) induced contraction in human, which induced greater contraction in human (pK(B) 9.1 and 8.3) than rat (pK(B) 6.8 and < 6) urinary bladder smooth muscle preparation in vitro. In agreement with functional data, in membrane preparations of CHO cells stably expressing the human NK2, receptors, both MEN13918 and MEN14268 potently inhibited the binding of agonist ([I-125]NKA, K-i 0.2 and 2.8 nM) and antagonist ([H-3]nepadutant, K-i 0.1 and 2.2 nM, [H-3]SR48968 K-i 0.4 and 6.9 nM) radioligands. Using site-directed mutagenesis and radioligands binding we identified six residues in the transmembrane (TM) helices that are critical determinants for the studied antagonists affinity. To visualize these experimental findings, we constructed a homology model based on the X-ray crystal structure of bovine rhodopsin and suggested a possible binding mode of these newly discovered antagonist ligands to the human tackykinin NK2 receptor. Both MEN13918 and MEN14268 bind amongst TM4 (Cys167Gly), TM5 (Tyr206Ala), TM6 (Tyr266Ala, Phe270Ala), and TM7 (Tyr289Phe, Tyr289Thr). MEN13918 and MEN14268 diverging binding profile at Y289 mutations in TM7 (Tyr289Phe, Tyr289Thr) suggests a relation of their different chemical moieties with this residue. Moreover, the different influence on binding of these two ligands by mutations located deep along the inner side of TM6 (Phe270Ala, Tyr266Ala, Trp263Ala) indicates a nonequivalent positioning, although occupying the same binding crevice. Furthermore, binding data indicate the Ile202Phe mutation, which mimics the wild-type rat NK2, receptor sequence, as a species selectivity determinant. In summary, data with mutant receptors describe, for these new tachykinin NK receptor antagonists, a binding site which is partially overlapping either with that of the cyclized peptide antagonist nepadutant (cyclo-{[Asn(beta-D-GlcNAc)-Asp-Trp-Phe-Dpr-Leu]cyclo(2beta-5beta)} or the nonpeptide antagonist SR48968 ((S)-N-methyl-N[4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzamide). (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:61 / 69
页数:9
相关论文
共 33 条
[1]  
AHARONY D, 1994, MOL PHARMACOL, V45, P9
[2]   A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor:: evidence from mutational analysis [J].
Bellucci, F ;
Meini, S ;
Cucchi, P ;
Catalani, C ;
Reichert, W ;
Zappitelli, S ;
Rotondaro, L ;
Quartara, L ;
Giolitti, A ;
Maggi, CA .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (03) :500-506
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist [J].
Catalioto, RM ;
Criscuoli, M ;
Cucchi, P ;
Giachetti, A ;
Giannotti, D ;
Giuliani, S ;
Lecci, A ;
Lippi, A ;
Patacchini, R ;
Quartara, L ;
Renzetti, AR ;
Tramontana, M ;
Arcamone, F ;
Maggi, CA .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (01) :81-91
[5]   Gly(166) in the NK1 receptor regulates tachykinin selectivity and receptor conformation [J].
Ciucci, A ;
Palma, C ;
Riitano, D ;
Manzini, S ;
Werge, TM .
FEBS LETTERS, 1997, 416 (03) :335-338
[6]   CHARACTERIZATION OF THE BINDING-SITES OF [H-3] SR-48968, A POTENT NONPEPTIDE RADIOLIGAND ANTAGONIST OF THE NEUROKININ-2 RECEPTOR [J].
EMONDSALT, X ;
GOLLIOT, F ;
POINTEAU, P ;
LEFUR, G ;
BRELIERE, JC .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 191 (03) :1172-1177
[7]  
GERARD NP, 1990, J BIOL CHEM, V265, P20455
[8]   Discovery of potent cyclic pseudopeptide human tachykinin NK-2 receptor antagonists [J].
Giannotti, D ;
Perrotta, E ;
Di Bugno, C ;
Nannicini, R ;
Harmat, NJS ;
Giolitti, A ;
Patacchini, R ;
Renzetti, AR ;
Rotondaro, L ;
Giuliani, S ;
Altamura, M ;
Maggi, CA .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (22) :4041-4044
[9]   Molecular determinants of peptide and nonpeptide NK-2 receptor antagonists binding sites of the human tachykinin NK-2 receptor by site-directed mutagenesis [J].
Giolitti, A ;
Cucchi, P ;
Renzetti, AR ;
Rotondaro, L ;
Zappitelli, S ;
Maggi, CA .
NEUROPHARMACOLOGY, 2000, 39 (08) :1422-1429
[10]   Monocyclic human tachykinin NK-2 receptor antagonists as evolution of a potent bicyclic antagonist: QSAR and site-directed mutagenesis studies [J].
Giolitti, A ;
Altamura, M ;
Bellucci, F ;
Giannotti, D ;
Meini, S ;
Patacchini, R ;
Rotondaro, L ;
Zappitelli, S ;
Maggi, CA .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (16) :3418-3429